Literature DB >> 11723235

Role of aspartate7.32(302) of the human gonadotropin-releasing hormone receptor in stabilizing a high-affinity ligand conformation.

B J Fromme1, A A Katz, R W Roeske, R P Millar, C A Flanagan.   

Abstract

Mammalian gonadotropin-releasing hormone (GnRH) receptors preferentially bind mammalian GnRH, which has Arg in position eight. The Glu(7.32(301)) residue, which determines selectivity of the mouse GnRH receptor for Arg(8)-containing GnRH, is Asp(7.32(302)) in the human GnRH receptor. We have confirmed that Asp(7.32(302)) confers selectivity of the human GnRH receptor for Arg(8) of GnRH and investigated the mechanism of this specificity using site-directed mutagenesis and ligand modification. We find that although Arg(8) and Asp(7.32(302)) are required for high-affinity binding of GnRH, conformationally constrained peptides, with D-amino acid substitutions in position six or with a 6,7 gamma-lactam, bind the human GnRH receptor with high affinity, which is independent of the presence of Asp(7.32(302)) in the receptor or Arg(8) in the ligand. The ability of the ligand constraints to compensate for the absence of both Arg(8) and Asp(7.32(302)) indicates that these residues both have roles in stabilizing a high affinity ligand conformation and that their roles are complementary. This suggests that the Arg(8) and Asp(7.32(302)) side chains interact to induce a high affinity conformation of native GnRH. Thus, Asp(7.32(302)) of the human GnRH receptor determines selectivity for mammalian GnRH by its ability to induce a high affinity conformation of its native ligand. However, this initial interaction seems not to contribute to the final ligand-receptor complex. We propose that Arg(8) interacts transiently with Asp(7.32(302)) to induce a high-affinity ligand conformation of GnRH, which then interacts with a binding pocket that is common for both constrained and unconstrained analogs of GnRH.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11723235     DOI: 10.1124/mol.60.6.1280

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  6 in total

1.  Gonadotropin-releasing hormone analog structural determinants of selectivity for inhibition of cell growth: support for the concept of ligand-induced selective signaling.

Authors:  Rakel López de Maturana; Adam J Pawson; Zhi-Liang Lu; Lindsay Davidson; Stuart Maudsley; Kevin Morgan; Simon P Langdon; Robert P Millar
Journal:  Mol Endocrinol       Date:  2008-05-08

2.  Molecular Coevolution of Neuropeptides Gonadotropin-Releasing Hormone and Kisspeptin with their Cognate G Protein-Coupled Receptors.

Authors:  Dong-Kyu Kim; Eun Bee Cho; Mi Jin Moon; Sumi Park; Jong-Ik Hwang; Jean-Luc Do Rego; Hubert Vaudry; Jae Young Seong
Journal:  Front Neurosci       Date:  2012-01-24       Impact factor: 4.677

Review 3.  Gonadotropin-Releasing Hormone (GnRH) Receptor Structure and GnRH Binding.

Authors:  Colleen A Flanagan; Ashmeetha Manilall
Journal:  Front Endocrinol (Lausanne)       Date:  2017-10-24       Impact factor: 5.555

4.  Probing the GnRH receptor agonist binding site identifies methylated triptorelin as a new anti-proliferative agent.

Authors:  Kevin Morgan; Samuel P Leighton; Robert P Millar
Journal:  J Mol Biochem       Date:  2012-06-16

5.  Evolution of vertebrate GnRH receptors from the perspective of a Basal vertebrate.

Authors:  Stacia A Sower; Wayne A Decatur; Nerine T Joseph; Mihael Freamat
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-19       Impact factor: 5.555

6.  R31C GNRH1 mutation and congenital hypogonadotropic hypogonadism.

Authors:  Luigi Maione; Frederique Albarel; Philippe Bouchard; Megan Gallant; Colleen A Flanagan; Regis Bobe; Joelle Cohen-Tannoudji; Rosario Pivonello; Annamaria Colao; Thierry Brue; Robert P Millar; Marc Lombes; Jacques Young; Anne Guiochon-Mantel; Jerome Bouligand
Journal:  PLoS One       Date:  2013-07-25       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.